Comprehensive Investigation of Natural Ligands as Inhibitors of β Secretase to Identify Alzheimer's Disease Therapeutics

被引:0
|
作者
Kushwah, Shikha [1 ]
Mani, Ashutosh [1 ]
机构
[1] Motilal Nehru Natl Inst Technol Allahabad, Dept Biotechnol, Prayagraj 211004, India
关键词
Alzheimer's disease; BACE1; amyloid-beta hypothesis; molecular docking; MD (molecular dynamics) simulation; herbal compounds; AMYLOID HYPOTHESIS; BACE1; PATHOGENESIS; PREDICTIONS; CURCUMIN; DOCKING;
D O I
10.2174/0115672050323622240705043337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Alzheimer's disease (AD) is an alarmingly prevalent worldwide neurological disorder that affects millions of people and has severe effects on cognitive functions. The amyloid hypothesis, which links AD to A beta (amyloid beta) plaque aggregation, is a well-acknowledged theory. The beta-secretase (BACE1) is the main cause of A beta production, which makes it a possible target for therapy. FDA-approved therapies for AD do exist, but none of them explicitly target BACE1, and their effectiveness is constrained and accompanied by adverse effects.Materials and Methods We determined the essential chemical components of medicinal herbs by conducting a thorough literature research for BACE1. Computational methods like molecular docking, ADMET (Absorption, distribution, metabolism, excretion, toxicity) screening, molecular dynamic simulations, and MMPBSA analysis were performed in order to identify the most promising ligands for beta-secretase.Results The results suggested that withasomniferol, tinosporide, and curcumin had better binding affinity with BACE1, suggesting their potential as therapeutic candidates against Alzheimer's disease.Conclusion Herbal therapeutics have immense applications in the treatment of chronic diseases like Alzheimer's disease, and there is an urgent need to assess their efficacy as therapeutics.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Beta-Secretase (BACE1) inhibitors for Alzheimer's disease
    Butler, Christopher R.
    Brodney, Michael A.
    O'Neill, Brian T.
    Helal, Christopher J.
    Lee, Chewah
    Witter, Kevin G.
    Lachapelle, Erik A.
    Allen, Martin P.
    Rogers, Bruce N.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [42] Synthesis of small molecule gamma-secretase inhibitors for Alzheimer's disease
    Pu, Jun
    Resnick, Lynn
    Aschmies, Suzan
    Atchison, Kevin
    Berkowitz, Joshua
    Caggiano, Thomas J.
    Chlenov, Micheal
    Diamantidis, George
    Harrison, Boyd
    Hu, Yun
    Huryn, Donna
    Jacobsen, J. Steven
    Jin, Mei
    Kreft, Anthony
    Lu, Peimin
    Martone, Robert
    Morris, Koi M.
    Sonnenberg-Reines, June
    Riddell, Dave
    Sabalski, Joan E.
    Sun, Shaiu-Ching
    Wagner, Erik
    Wang, Elizabeth
    Xu, Zheng
    Zhou, Hua
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 767 - 767
  • [43] Beta-secretase (BACE1) inhibitors for Alzheimer's disease
    Butler, Christopher
    Brodney, Michael
    Ogilvie, Kevin
    Martinez-Alsina, Luis
    Helal, Christopher
    Nolan, Charles
    Parris, Kevin
    Vajdos, Felix
    Gonzales, Cathleen
    Robshaw, Ashley
    Doran, Shawn
    Beck, Elizabeth
    Barreiro, Gabriela
    Riddell, David
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [44] Cholinesterase inhibitors as Alzheimer's therapeutics
    Sharma, Kamlesh
    MOLECULAR MEDICINE REPORTS, 2019, 20 (02) : 1479 - 1487
  • [45] Amino imidazoles as b-secretase inhibitors for treatment of Alzheimer's disease
    Brodney, Michael
    Borzilleri, Kris
    Capetta, Steven
    Chenard, Lois
    Coffman, Karen
    Dorf, Peter
    Dutra, Jason
    Efremov, Ivan
    Helal, Chris
    Kauffman, Gregory
    Lanyon, Lorraine
    Liston, Dane
    Liu, JianHua
    Nelson, Frederick
    Oborski, Christine
    O'Neill, Brian
    O'Sullivan, Theresa
    Sahagan, Barbara
    Vajdos, Felix
    Wessel, Matt
    Withka, Jane
    O'Connell, Thomas N.
    Wang, Hong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [46] Therapeutic intervention for Alzheimer's disease with γγ-secretase inhibitors: still a viable option?
    Imbimbo, Bruno P.
    Panza, Francesco
    Frisardi, Vincenza
    Solfrizzi, Vincenzo
    D'Onofrio, Grazia
    Logroscino, Giancarlo
    Seripa, Davide
    Pilotto, Alberto
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 325 - 341
  • [47] Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease
    Beher, D
    Graham, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (11) : 1385 - 1409
  • [48] Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease
    Asberom, Theodros
    Zhao, Zhiqiang
    Bara, Thomas A.
    Clader, John W.
    Greenlee, William J.
    Hyde, Lynn A.
    Josien, Hubert B.
    Li, Wei
    McPhail, Andrew T.
    Nomeir, Amin A.
    Parker, Eric M.
    Rajagopalan, Murali
    Song, Lixin
    Wong, Gwendolyn T.
    Zhang, Lili
    Zhang, Qi
    Pissarnitski, Dmitri A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (02) : 511 - 516
  • [49] Targeting γ-secretase for Alzheimer's disease
    Wolfe, Michael S.
    Alzheimer: 100 Years and Beyond, 2006, : 265 - 268
  • [50] β-secretase -: A target for Alzheimer's disease
    Citron, M
    MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 79 - 83